U.S. Appeals Court Says Eisai Patents Can Be Challenged By Teva
This article was originally published in PharmAsia News
Executive Summary
A U.S. appeals court ruled Eisai patents for its Aricept (donepezil) Alzheimer's drug are open to challenge by generics maker Teva Pharmaceutical Industries of Israel
A U.S. appeals court ruled Eisai patents for its Aricept (donepezil) Alzheimer's drug are open to challenge by generics maker Teva Pharmaceutical Industries of Israel. The U.S. court overturned a lower court decision rejecting Teva's challenge. The case was seen as key to whether Ranbaxy Laboratories of India or Teva reached the market first with a generic. (Click here for more) "Teva Can Challenge Eisai Aricept Patents, Court Says" - Bloomberg (U.S.) (10/6/10) |